What's in Dai, Guanghai's pipeline?

Dai, Guanghai has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Dai, Guanghai's portfolio?

Top competitors by shared drug class: Akeso, Aravive, Inc., Athenex, Inc., Barts & The London NHS Trust, BeyondSpring Pharmaceuticals Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dai-guanghai.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Dai, Guanghai — Portfolio Competitive Intelligence Brief

Dai, Guanghai pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Paclitaxel (albumin-bound)	Paclitaxel (albumin-bound)	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Akeso · 1 shared drug class
Aravive, Inc. · 1 shared drug class
Athenex, Inc. · 1 shared drug class
Barts & The London NHS Trust · 1 shared drug class
BeyondSpring Pharmaceuticals Inc. · 1 shared drug class
Bio-Thera Solutions · 1 shared drug class
Fujian Medical University · 1 shared drug class
Guangzhou Double Bioproducts Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dai, Guanghai:

Cite this brief

Drug Landscape (2026). Dai, Guanghai — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dai-guanghai. Accessed 2026-05-15.